Lotte Corporation said it decided to enter into a funding support agreement for loan debt of its subsidiary Lotte Biologics Co., Ltd., according to a filing dated October 22, 2026.

Lotte Corporation disclosed on October 22, 2026 that it decided to enter into an agreement to supplement funds if its subsidiary Lotte Biologics Co., Ltd. has insufficient repayment sources for its financial institution loans. The amount covered is the total loan debt, including loan principal of KRW 282.5 billion and interest, and the company said the ratio to equity is 3.00% based on loan principal. The company added that the amount and period may change in part depending on the terms of the individual loan contracts.

1. 01

   The company said it decided to provide an agreement under which it would supplement funds if the repayment sources of its subsidiary Lotte Biologics Co., Ltd. are insufficient to meet loan contract debts with financial institutions, including HSBC.

2. 02

   The amount covered by the funding support agreement is the total debt under the loan contracts, including loan principal of KRW 282.5 billion, interest, fees and other financial costs.

3. 03

   The company said the ratio to equity is 3.00% based on loan principal of KRW 282.5 billion.

4. 04

   The company said Lotte Biologics Co., Ltd. plans to borrow funds from financial institutions from October 2026 end to December, and that the amount and period of the agreement may change in part depending on the terms of the individual loan contracts.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Funding support amount (loan principal)

KRW 282.5 billion

Equity

KRW 9.42 trillion

Ratio to equity (based on loan principal)

3.00%

Funding support obligation period

From the signing date of the funding support agreement until full repayment of the loan contract debts (expected October 2026 to November 2029)

Independent (outside) directors attending board meeting

4 attended, 0 absent

Filing facts

Filing type

Material Management Information

Report name

Material Management Information for Investment Decisions

Filed

Oct 22, 2026

Receipt number

20261022800609